The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 585-592

  Chiu, Chih Chiang ^a,b,c   Chen, Chun Hsin ^b,d   Huang, Ming Chyi ^a,b   Chen, Po Yu ^a   Tsai, Chang Jer ^a,e   Lu, Mong Liang ^b,d  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

antipsychotics; hyperuricemia; metabolic syndrome; schizophrenia; uric acid

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; URIC ACID;

ADULT; ANTHROPOMETRY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

ADULT; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; SEX FACTORS; URIC ACID;

EID: 84865861621     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182664e64     Document Type: Article

References (67)

1. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
2. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-760.
3. Suvisaari JM, Saarni SI, Perala J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry. 2007;68:1045-1055.
4. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
5. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1-17.
6. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
7. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
8. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
9. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-3072.
10. Lyketsos CG, Dunn G, Kaminsky MJ, et al. Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics. 2002;43:24-30.
11. De Hert M, Peuskens B, van Winkel R, et al. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res. 2006;88:222-226.
12. Liu PW, Chang TY, Chen JD. Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism. 2010;59:802-807.
13. Numata T, Miyatake N, Wada J, et al. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract. 2008;80:e1Ye5.
14. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928-933.
15. Kawamoto R, Tomita H, Oka Y, et al. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med. 2006;45:605-614.
16. Onat A, Uyarel H, Hergenc G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens. 2006;19:1055-1062.
17. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37: 883-889.
18. Ishizaka N, Ishizaka Y, Toda E, et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038-1044.
19. Chen LK, Lin MH, Lai HY, et al. Uric acid: a surrogate of insulin resistance in older women. Maturitas. 2008;59:55-61.
20. Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845-852.
21. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14:615-631.
22. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62:205-212.
23. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80: 29-39.
24. Yao JK, Dougherty GG Jr, Reddy RD, et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS One. 2010;5:e9508.
25. Nagamine T. Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study. Neuropsychiatr Dis Treat. 2010;6:281-288.
26. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13.
27. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27:1182-1186.
28. Huang MC, Lu ML, Tsai CJ, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand. 2009;120:274-280.
29. Chien KL, Hsu HC, Sung FC, et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005;183:147-155.
30. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc. 2006;69:512-516.
31. Tamba S, Nishizawa H, Funahashi T, et al. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med. 2008;47:1175-1180.
32. Kang YH, Min HG, Kim IJ, et al. Comparison of alanine aminotransferase, white blood cell count, and uric acid in their association with metabolic syndrome: a study of Korean adults. Endocr J. 2008;55:1093-1102.
33. Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008-3011.
34. Cook DG, Shaper AG, Thelle DS, et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J. 1986;62:1001-1006.
35. Golembiewska E, Ciechanowski K, Safranow K, et al. Renal handling of uric acid in patients with type 1 diabetes in relation to glycemic control. Arch Med Res. 2005;36:32-35.
36. Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010;123:957-961.
37. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442-447.
38. Hopps E, Noto D, Caimi G, et al. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2010;20:72-77.
39. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705-712.
40. Grattagliano I, Palmieri VO, Portincasa P, et al. Oxidative stressYinduced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491-504.
41. Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11-17.
42. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821.
43. De Luca G, Secco GG, Santagostino M, et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis. 2012;22(5):426-433.
44. Kang DH, Park SK, Lee IK, et al. Uric acidYinduced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553-3562.
45. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739-1742.
46. Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidaseYmediated oxidative/ nitrosative stress. Am J Physiol Cell Physiol. 2007;293:C584YC596.
47. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-1761.
48. Yiginer O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 2008;97:334-340.
49. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55:1293-1301.
50. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878-893.
51. Srivastava N, Barthwal MK, Dalal PK, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl). 2001;158:140-145.
52. Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1677-1681.
53. Mahadik SP, Pillai A, Joshi S, et al. Prevention of oxidative stressYmediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry. 2006;18:119-131.
54. Singh OP, Chakraborty I, Dasgupta A, et al. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J Psychiatry. 2008;50:171-176.
55. Dadheech G, Mishra S, Gautam S, et al. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry. 2008;50:16-20.
56. Nakano Y, Yoshimura R, Nakano H, et al. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum Psychopharmacol. 2010;25:139-144.
57. Li XF, Zheng YL, Xiu MH, et al. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1064-1067.
58. Reddy R, Reddy R. Antioxidant therapeutics for schizophrenia. Antioxid Redox Signal. 2011;15:2047-2055.
59. Pillai A, Parikh V, Terry AV Jr, et al. Long-term antipsychotic treatments and crossover studies in rats: differential effects of ypical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res. 2007;41:372-386.
60. Park SW, Lee CH, Lee JG, et al. Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neurosci Res. 2011;69:283-290.
61. Pepe H, Balci SS, Revan S, et al. Comparison of oxidative stress and antioxidant capacity before and after running exercises in both sexes. Gend Med. 2009;6:587-595.
62. Habif S, Mutaf I, Turgan N, et al. Age and gender dependent alterations in the activities of glutathione related enzymes in healthy subjects. Clin Biochem. 2001;34:667-671.
63. Harish G, Venkateshappa C, Mahadevan A, et al. Glutathione metabolism is modulated by postmortem interval, gender difference and agonal state in postmortem human brains. Neurochem Int. 2011;59(7):1029-1042.
64. Sartori-Valinotti JC, Iliescu R, Fortepiani LA, et al. Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin Exp Pharmacol Physiol. 2007;34:938-945.
65. Chakraborti A, Gulati K, Banerjee BD, et al. Possible involvement of free radicals in the differential neurobehavioral responses to stress in male and female rats. Behav Brain Res. 2007;179:321-325.
66. Yao JK, Dougherty GG Jr, Reddy RD, et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS One. 2010;5:e9508.
67. Ryu S, Song J, Choi BY, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol. 2007;17:245-252.